Showing 2011-2020 of 2235 results for "".
- Pulse Biosciences Receives European Clearance for CellFX Systemhttps://modernaesthetics.com/news/pulse-biosciences-receives-european-clearance-for-cellfx-system/2473050/Pulse Biosciences, Inc. will proceed with its planned controlled launch of the CellFX System to medical practices within the European Union (EU), now that it has received CE mark for the system. The European clearance is for the treatment of general dermatologic conditions, includi
- Meet CoolSculpting Elitehttps://modernaesthetics.com/news/meet-coolsculpting-elite/2473048/Allergan Aesthetics, an AbbVie company, is launching CoolSculptingElite, its next generation fat reduction system with applicators designed to complement the body's natural curves. The system will launch with a new applicator collection, which includes seven different shapes a
- Medspa COVID-19 Safety Procedures: A Checklist Reviewhttps://modernaesthetics.com/news/medspa-covid-19-safety-procedures-a-checklist-review/2473046/COVID-19 is a viral infection that spreads primarily by distribution of droplets from our mouths. When an infected person coughs, sneezes, breathes, drinks, eats, talks, sings, yells, etc., s/he is producing sprays and mists of saliva droplets that carry the virus. When another person inhale
- Allergan Aesthetics Enters Into Option to Acquire Cypris Medicalhttps://modernaesthetics.com/news/allergan-aesthetics-enters-into-option-to-acquire-cypris-medical/2473045/Allergan Aesthetics, an AbbVie company has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago. Following the completion of a clinical trial to be initiated in 2021, Allergan Aesthetics will have the right to exercis
- Four Years Running: Alastin Leads in Growthhttps://modernaesthetics.com/news/four-years-running-alastin-leads-in-growth/2473044/Alastin Skincare®, Inc. is the Fastest Growing Brand in the US Professional Skincare Market for the fourth year in a row. That’s according to the latest rankings from consulting and research firm Kline Group's 2020 Professional Skincare: US Market Analysis and Opportunitie
- Merz and Candela Announce New Collabhttps://modernaesthetics.com/news/merz-and-candela-announce-new-collab/2473041/Merz Aesthetics and Candela Corporation are joining forces. As part of the collab, sales reprentatives from each company will now have the ability to promote products from both organizations. The companies are not formally changing their structure or formally integr
- Are COVID-19 Vaccines Risky for Dermal Filler Patients? Dermatologists Weigh the Existing Evidencehttps://modernaesthetics.com/news/are-covid-19-vaccines-risky-for-dermal-filler-patients-dermatologists-weigh-the-existing-evidence/2473039/As case reports of facial swelling in patients with a history of dermal filler treatment who received Moderna’s COVID-19 vaccine accrue, dermatologists are devising new protocols for how to best address this potential phenomenon, including the optimal timing of fillers and vaccines, updated
- Soliton Taps Sean J. Shapiro as Vice President of Saleshttps://modernaesthetics.com/news/soliton-taps-sean-j-shapiro-as-vice-president-of-sales/2473037/Sean J. Shapiro is Soliton, Inc’s New Vice President of Sales, effective January 1, 2021. "We are very excited to have Sean join our team during this pivotal time for the company as we anticipate clearance of our 510(k) application for cellulite reduction duri
- Are COVID-19 Vaccines Safe for Filler Patients?https://modernaesthetics.com/news/facial-fillers-and-covid-19-vaccines-is-there-a-risk-for-adverse-reactions/2473036/Three patients with dermal fillers have had adverse reactions to the Moderna COVID-19 vaccine, according to the Aesthetic Society. The FDA intends to note this in its prescribing information. There have been no reported cases in patients receiving the Pfizer COVID-19 vaccine.
- Phase 2 DaxibotulinumtoxinA Data Highlight Efficacy for Upper Facial Lineshttps://modernaesthetics.com/news/phase-2-daxibotulinumtoxina-data-highlight-efficacy-for-upper-facial-lines/2473032/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48